BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Active, not recruiting · NCT06205706 · Registry updated 2025-09-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-09-19 | NCT06205706 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioInvent International AB | 5 |
| Merck Sharp & Dohme LLC | 650 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| HM Sanchinarro | Madrid | Spain | 2 |
| Hospital Fundacion Jimenez Diaz | Madrid | Spain | 5 |
| Hospital HM Nou Delfos | Barcelona | Spain | 5 |
| Hospital Universitario Virgen del Rocio | Seville | Spain | 42 |
| Karolinska University Hospital, Solna | Stockholm | Sweden | 5 |
| Lund University Hospital | Lund | Sweden | 13 |
| Rigshospitalet | Copenhagen | Denmark | 84 |
| Universitätsklinikum Essen | Essen | Germany | 27 |